Contact
searchSearch
HMP Global
Login
Mansoor Raza Mirza, MD, Copenhagen University Hospital, Denmark
Conference Coverage
Beyond Immunotherapy Treatment for Patients With Recurrent Metastatic Endometrial Cancer
02/24/2023
At the 2023 ESMO Gynecological Cancers Congress, Mansoor Raza Mirza, MD, discusses the role of HER2, p53, and other molecular targets in treating patients with recurrent, metastatic endometrial cancer.
At the 2023 ESMO Gynecological Cancers Congress, Mansoor Raza Mirza, MD, discusses the role of HER2, p53, and other molecular targets in treating patients with recurrent, metastatic endometrial cancer.
At the 2023 ESMO Gynecological...
02/24/2023
Oncology
Conference Coverage
Impact of BRCA Mutation Location on PARP Inhibitor Efficacy for Patients with Advanced Ovarian Cancer
02/23/2023
According to study results presented at the 2023 ESMO Gynecological Cancers Congress, the location and type of BRCA mutation may impact the effectiveness of PARP inhibitor treatment for patients with advanced ovarian cancer.
According to study results presented at the 2023 ESMO Gynecological Cancers Congress, the location and type of BRCA mutation may impact the effectiveness of PARP inhibitor treatment for patients with advanced ovarian cancer.
According to study results...
02/23/2023
Oncology
Conference Coverage
Optimal Treatment Modality for Patients With Advanced Cervical Cancer
02/23/2023
Data presented at the 2023 ESMO Gynecological Cancers Congress shows survival outcomes were improved among patients with late-stage cervical cancer who received adjuvant chemoradiotherapy compared with other treatment modalities.
Data presented at the 2023 ESMO Gynecological Cancers Congress shows survival outcomes were improved among patients with late-stage cervical cancer who received adjuvant chemoradiotherapy compared with other treatment modalities.
Data presented at the 2023 ESMO...
02/23/2023
Oncology
Conference Coverage
Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer
02/23/2023
According to study results presented at the 2023 ESMO Gynecological Cancers Congress, patients with recurrent or metastatic cervical cancer treated with tisotumab vedotin experienced clinically meaningful and durable anti-tumor activity.
According to study results presented at the 2023 ESMO Gynecological Cancers Congress, patients with recurrent or metastatic cervical cancer treated with tisotumab vedotin experienced clinically meaningful and durable anti-tumor activity.
According to study results...
02/23/2023
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use